Bristol Myers Squibb announces opdivo's cumulative five year survival rate

Bristol Myers Squibb (NYSE: BMY) today released the results of a three-stage, long-term clinical efficacy study and safety review of checkmate-017 and checkmate-057 in patients with previously treated advanced non-small cell lung cancer (NSCLC) After five years of treatment, patients treated with opdivo (nivolumab) had an increased overall long-term survival (OS) compared with patients treated with docetaxel The five-year OS rate of opdivo was 13.4% and that of docetaxel was 2.6% Opdivo was observed to increase the OS rate in all subgroups The safety of opdivo in the course of treatment was consistent with the results of second-line NSCLC reported previously, and no new safety signal was found during the extended follow-up Of the patients still under study, only 2 out of 70 selected treatment-related new AE between the 3rd and 4th year, and of the 55 patients still under study, no need to select treatment-related new AE between the 4th and 5th year was reported 32.2% of the patients with objective response to opdivo continued to respond within 5 years 0% of the patients who had objective response to docetaxel still had response at 5 years The median response duration was 19.9 months in patients treated with opdivo and 5.6 months in patients treated with docetaxel Dr Scott geitinger, Professor of medical oncology at Yale cancer center, commented: "the cumulative five-year checkmate-017 and 057 data highlight the long-term efficacy of opdivo compared with traditional chemotherapy in this patient population." Dr Sabine Maier, head of breast cancer development at Bristol Myers Squibb, said: "patients who have undergone standard chemotherapy have never had a five-year survival rate of less than 5% Since the US Food and Drug Administration approved opdivo for the treatment of second-line non-small cell lung cancer in 2015, it has become an important treatment option for patients who have undergone standard chemotherapy The long-term survival of these two studies in a large population of patients confirmed the durability of the treatment regimen of opdivo The durability of Opdivo has been confirmed in a variety of tumor types and treatments This summary analysis is the longest follow-up study of NSCLC patients receiving immunotherapy in clinical phase 3 randomized trials Today (September 10) will give an oral report at the 20th World Lung Cancer Congress (wclc) of the International Association for lung cancer research (IASLC) held in Barcelona, Spain, from 12:00-12:10 noon CET (BIOON Com) original address: Bristol Myers Squibb official website